{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:07:30Z","timestamp":1787933250571,"version":"build-2784847793"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cerebral adrenoleukodystrophy is an inflammatory demyelinating condition that is the result of a mutation in the X-linked ABCD1 gene, a peroxisomal very long chain fatty acid transporter. Although mutations in this gene result in adrenal insufficiency in the majority of affected individuals, 40% of those affected develop the demyelinating cerebral form, cerebral adrenoleukodystrophy (CALD). CALD is characterized by imaging findings of demyelination and contrast enhancement on magnetic resonance imaging (MRI). Although allogeneic hematopoietic cell transplantation can arrest progression of CALD early in its course, there is no accepted therapy for patients with advanced CALD. Mesenchymal stem cells (MSCs) have been used in a variety of clinical trials to capitalize on their anti-inflammatory properties as well as promote tissue repair. We delivered MSCs via intrathecal (IT) route to two boys with rapidly advancing CALD. The first boy received three doses 1 week apart, whereas the second boy received a single dose of IT MSCs. We note delivery of IT MSCs was feasible and without complication. Follow-up MRI scans after IT MSC delivery showed progressive demyelination in the first patient and no change in demyelination or contrast enhancement in the second patient. Although the infusion of IT MSCs was safe, it did not halt CALD progression in this setting, and future studies should focus on patient selection and dose optimization.<\/jats:p>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Lessons learned Mesenchymal stem cells can be safely delivered to boys with cerebral adrenoleukodystrophy. Advanced cerebral adrenoleukodystrophy may not respond to intrathecal injection. \u00a0Significance statementCerebral adrenoleukodystrophy (CALD) is characterized by imaging findings of demyelination, inflammation, and contrast enhancement on magnetic resonance imaging (MRI). There is no accepted therapy for patients with advanced cerebral adrenoleukodystrophy. Mesenchymal stem cells (MSCs) were delivered via intrathecal (IT) route to two boys with rapidly advancing CALD in hopes of utilizing their anti-inflammatory ability to halt disease progression. The delivery of IT MSC was feasible and without complication, although follow-up MRI scans after IT MSC delivery showed progressive demyelination in both patients. This may have been due to the advanced nature of disease in the patients or an inadequate cell dose.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/sctm.19-0304","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T08:41:18Z","timestamp":1580892078000},"page":"554-558","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Failure of intrathecal allogeneic mesenchymal stem cells to halt progressive demyelination in two boys with cerebral adrenoleukodystrophy"],"prefix":"10.1093","volume":"9","author":[{"given":"Ashish","family":"Gupta","sequence":"first","affiliation":[{"name":"1 Division of Pediatric Blood and Marrow Transplant University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[{"name":"1 Division of Pediatric Blood and Marrow Transplant University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weston P.","family":"Miller","sequence":"additional","affiliation":[{"name":"1 Division of Pediatric Blood and Marrow Transplant University of Minnesota, Minneapolis, Minnesota"},{"name":"2 Sangamo Therapeutics, Richmond, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave R.","family":"Nascene","sequence":"additional","affiliation":[{"name":"3 Department of Diagnostic Radiology University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald V.","family":"Raymond","sequence":"additional","affiliation":[{"name":"4 Department of Neurology Johns Hopkins Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Loes","sequence":"additional","affiliation":[{"name":"3 Department of Diagnostic Radiology University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"McKenna","sequence":"additional","affiliation":[{"name":"5 Department of Laboratory Medicine and Pathology, Transfusion Medicine University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[{"name":"1 Division of Pediatric Blood and Marrow Transplant University of Minnesota, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2022022809311955200_sct312664-bib-0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1750-3639.2010.00391.x","article-title":"Biochemical aspects of X-linked adrenoleukodystrophy","volume":"20","author":"Kemp","year":"2010","journal-title":"Brain Pathol"},{"key":"2022022809311955200_sct312664-bib-0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-7-51","article-title":"X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management","volume":"7","author":"Engelen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2022022809311955200_sct312664-bib-0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ymgme.2015.01.014","article-title":"Disease specific therapies in leukodystrophies and leukoencephalopathies","volume":"114","author":"Helman","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2022022809311955200_sct312664-bib-0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.21391","article-title":"Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?","volume":"63","author":"Eichler","year":"2008","journal-title":"Ann Neurol"},{"key":"2022022809311955200_sct312664-bib-0005","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1093\/brain\/awv250","article-title":"Brain endothelial dysfunction in cerebral adrenoleukodystrophy","volume":"138","author":"Musolino","year":"2015","journal-title":"Brain"},{"key":"2022022809311955200_sct312664-bib-0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pediatrneurol.2007.06.011","article-title":"Immune response in leukodystrophies","volume":"37","author":"Eichler","year":"2007","journal-title":"Pediatr Neurol"},{"key":"2022022809311955200_sct312664-bib-0007","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00005072-199211000-00007","article-title":"The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications","volume":"51","author":"Powers","year":"1992","journal-title":"J Neuropathol Exp Neurol"},{"key":"2022022809311955200_sct312664-bib-0008","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/eji.201848043","article-title":"Cerebral adrenoleukodystrophy is associated with loss of tolerance to profilin","volume":"49","author":"Orchard","year":"2019","journal-title":"Eur J Immunol"},{"key":"2022022809311955200_sct312664-bib-0009","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/awy127","article-title":"Impaired plasticity of macrophages in X-linked adrenoleukodystrophy","volume":"141","author":"Weinhofer","year":"2018","journal-title":"Brain"},{"key":"2022022809311955200_sct312664-bib-0010","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/sctm.19-0073","article-title":"Concise review: mesenchymal stromal cells anno 2019: dawn of the therapeutic era?","volume":"8","author":"Hoogduijn","year":"2019","journal-title":"Stem Cells Translational Medicine"},{"key":"2022022809311955200_sct312664-bib-0011","first-page":"1","article-title":"Safety and feasibility of repeated intrathecal allogeneic bone marrow-derived mesenchymal stromal cells in patients with neurological diseases","volume":"2019","author":"Pan","year":"2019","journal-title":"Stem Cells Int"},{"key":"2022022809311955200_sct312664-bib-0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2022022809311955200_sct312664-bib-0013","first-page":"1761","article-title":"Adrenoleukodystrophy: a scoring method for brain MR observations","volume":"15","author":"Loes","year":"1994","journal-title":"AJNR Am J Neuroradiol"},{"key":"2022022809311955200_sct312664-bib-0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/14653249.2011.623691","article-title":"Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing","volume":"14","author":"Francois","year":"2012","journal-title":"Cytotherapy"},{"key":"2022022809311955200_sct312664-bib-0015","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1089\/ten.2006.12.2161","article-title":"Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells","volume":"12","author":"Zhang","year":"2006","journal-title":"Tissue Eng"},{"key":"2022022809311955200_sct312664-bib-0016","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1207285","article-title":"Cord-blood engraftment with ex vivo mesenchymal-cell coculture","volume":"367","author":"Lima","year":"2012","journal-title":"N Engl J Med"},{"key":"2022022809311955200_sct312664-bib-0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2174\/1574888X09666140616125446","article-title":"The roles of mesenchymal stem cells in tissue repair and disease modification","volume":"9","author":"Wu","year":"2014","journal-title":"Curr Stem Cell Res Ther"},{"key":"2022022809311955200_sct312664-bib-0018","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.exphem.2008.03.006","article-title":"Immunosuppression by mesenchymal stromal cells: from culture to clinic","volume":"36","author":"Jones","year":"2008","journal-title":"Exp Hematol"},{"key":"2022022809311955200_sct312664-bib-0019","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/eji.200636416","article-title":"Immunoregulatory function of mesenchymal stem cells","volume":"36","author":"Uccelli","year":"2006","journal-title":"Eur J Immunol"},{"key":"2022022809311955200_sct312664-bib-0020","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.yexcr.2006.03.019","article-title":"Immune modulation by mesenchymal stem cells","volume":"312","author":"Rasmusson","year":"2006","journal-title":"Exp Cell Res"},{"key":"2022022809311955200_sct312664-bib-0021","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/scd.2007.0065","article-title":"Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells","volume":"16","author":"Chen","year":"2007","journal-title":"Stem Cells Dev"},{"key":"2022022809311955200_sct312664-bib-0022","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ana.25302","article-title":"Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis","volume":"84","author":"Oh","year":"2018","journal-title":"Ann Neurol"},{"key":"2022022809311955200_sct312664-bib-0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.advms.2016.12.004","article-title":"Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: an open label study","volume":"62","author":"Hlebokazov","year":"2017","journal-title":"Adv Med Sci"},{"key":"2022022809311955200_sct312664-bib-0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/sctm.17-0041","article-title":"Multiple autologous bone marrow-derived CD271(+) mesenchymal stem cell transplantation overcomes drug-resistant epilepsy in children","volume":"7","author":"Milczarek","year":"2018","journal-title":"Stem Cells Translational Medicine"},{"key":"2022022809311955200_sct312664-bib-0025","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2011-01-329235","article-title":"Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report","volume":"118","author":"Miller","year":"2011","journal-title":"Blood"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.19-0304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sctm.19-0304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sctm.19-0304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/5\/554\/42628019\/stcltm_9_5_554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/9\/5\/554\/42628019\/stcltm_9_5_554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:38:27Z","timestamp":1646041107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/9\/5\/554\/6406815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.19-0304","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"2019-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}